Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ventrus gains on PhIII anal fissures data for diltiazem cream; awaits possible replication of EU study

This article was originally published in Scrip

Executive Summary

Ventrus Biosciences, a US firm focused on late-stage GI compounds, said that its diltiazem cream for anal fissures, VEN 307, met the primary endpoint, showing a statistically significant reduction in anal pain on defecation after four weeks compared to placebo in a pivotal Phase III trial conducted in Europe. The company’s share price shot up 19% in early trading and closed up $1.62 (15%), to $12.58 as the firm moves toward a US NDA filing.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts